A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity

Vaccine

Volumn 29, Issue 32, 2011, Pages 5250-5259

  Sánchez Palomino, Sonsoles ^a   Massanella, Marta ^b   Carrillo, Jorge ^b   García, Ana ^a   García, Felipe ^a   González, Nuria ^c   Merino, Alberto ^a   Alcamí, José ^c   Bofill, Margarita ^b,d   Yuste, Eloísa ^a   Gatell, Josep M ^a   Clotet, Bonaventura ^b   Blanco, Julià ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Cell to cell viral transmission; Humoral responses; T lymphocytes

Indexed keywords

CD4 ANTIGEN; IMMUNOGLOBULIN G; VIRUS ENVELOPE PROTEIN;

ADULT; ARTICLE; ASSAY; BINDING SITE; CD4+ T LYMPHOCYTE; CELL FUSION; CLADISTICS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMORAL IMMUNITY; MALE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS PARTICLE;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BINDING SITES, ANTIBODY; CD4-POSITIVE T-LYMPHOCYTES; CELL FUSION; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; MACROPHAGES; MALE; MEMBRANE FUSION; SYNAPSES;

EID: 80955179554     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.016     Document Type: Article

References (37)

1. Ugolini S., Mondor I., Parren P.W., Burton D.R., Tilley S.A., Klasse P.J., et al. Inhibition of virus attachment to CD4+target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. J Exp Med 1997, 186:1287-1298.
2. Valenzuela A., Blanco J., Krust B., Franco R., Hovanessian A.G. Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells. J Virol 1997, 71:8289-8298.
3. Salzwedel K., Smith E.D., Dey B., Berger E.A. Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. J Virol 2000, 74:326-333.
4. Spivak A.M., Sydnor E.R., Blankson J.N., Gallant J.E. Seronegative HIV-1 infection: a review of the literature. AIDS 2010, 24:1407-1414.
5. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
6. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
7. Binley J.M., Lybarger E.A., Crooks E.T., Seaman M.S., Gray E., Davis K.L., et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 2008, 82:11651-11668.
8. Dhillon A.K., Donners H., Pantophlet R., Johnson W.E., Decker J.M., Shaw G.M., et al. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 2007, 81:6548-6562.
9. Li Y., Svehla K., Louder M.K., Wycuff D., Phogat S., Tang M., et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 2009, 83:1045-1059.
10. González N., Bermejo M., Calonge E., Jolly C., Arenzana-Seisdedos F., Pablos J.L., et al. SDF-1/CXCL12 production by mature dendritic cells inhibits the propagation of X4-tropic HIV-1 isolates at the dendritic cell-T-cell infectious synapse. J Virol 2010, 84:4341-4351.
11. Izquierdo-Useros N., Naranjo-Gómez M., Erkizia I., Puertas M.C., Borràs F.E., Blanco J., et al. HIV and mature dendritic cells: Trojan exosomes riding the Trojan horse?. PLoS Pathog 2010, 6:e1000740.
12. Piguet V., Sattentau Q. Dangerous liaisons at the virological synapse. J Clin Invest 2004, 114:605-610.
13. Puigdomènech I., Massanella M., Izquierdo-Useros N., Ruiz-Hernandez R., Curriu M., Bofill M., et al. HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4. Retrovirology 2008, 5:32.
14. Blanco J., Bosch B., Fernández-Figueras M.T., Barretina J., Clotet B., Esté J.A. High level of coreceptor-independent HIV transfer induced by contacts between primary CD4 T cells. J Biol Chem 2004, 279:51305-51314.
15. Bosch B., Clotet-Codina I., Blanco J., Pauls E., Coma G., Cedeño S., et al. Inhibition of human immunodeficiency virus type 1 infection in macrophages by an alpha-v integrin blocking antibody. Antiviral Res 2006, 69:173-180.
16. Chen P., Hübner W., Spinelli M.A., Chen B.K. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J Virol 2007, 81:12582-12595.
17. Ruggiero E., Bona R., Muratori C., Federico M. Virological consequences of early events following cell-cell contact between human immunodeficiency virus type 1-infected and uninfected CD4+cells. J Virol 2008, 82:7773-7789.
18. Massanella M., Puigdomènech I., Cabrera C., Fernandez-Figueras M.T., Aucher A., Gaibelet G., et al. Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells. AIDS 2009, 23:183-188.
19. Martin N., Welsch S., Jolly C., Briggs J.A., Vaux D., Sattentau Q.J. Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J Virol 2010, 84:3516-3527.
20. Blanco J., Barretina J., Clotet B., Esté J.A. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism. J Leukoc Biol 2004, 76:804-811.
21. Newman R.M., Hall L., Connole M., Chen G.L., Sato S., Yuste E., et al. Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5alpha. Proc Natl Acad Sci USA 2006, 103:19134-19139.
22. Garcia-Perez J., Sanchez-Palomino S., Perez-Olmeda M., Fernandez B., Alcami J. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1. J Med Virol 2007, 79:127-137.
23. González N., Pérez-Olmeda M., Mateos E., Cascajero A., Alvarez A., Spijkers S., et al. A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. J Antimicrob Chemother 2010, 64:2493-2501.
24. Fenyö E.M., Heath A., Dispinseri S., Holmes H., Lusso P., Zolla-Pazner S., et al. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One 2009, 4:e4505.
25. Blanco J., Canela E.I., Mallol J., Lluís C., Franco R. Characterization of adenosine receptors in brush-border membranes from pig kidney. Br J Pharmacol 1992, 107:671-678.
26. Puigdomènech I., Massanella M., Cabrera C., Clotet B., Blanco J. On the steps of cell-to-cell HIV transmission between CD4 T cells. Retrovirology 2009, 6:89.
27. Chen W., Zhu Z., Feng Y., Dimitrov D.S. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci USA 2008, 105:17121-17126.
28. Fouts T.R., Binley J.M., Trkola A., Robinson J.E., Moore J.P. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J Virol 1997, 71:2779-2785.
29. Bosch B., Blanco J., Pauls E., Clotet-Codina I., Armand-Ugón M., Grigorov B., et al. Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein. Antimicrob Agents Chemother 2005, 49:4296-4304.
30. Blanco J., Clotet-Codina I., Bosch B., Armand-Ugón M., Clotet B., Esté J.A. Multiparametric assay to screen and dissect the mode of action of anti-human immunodeficiency virus envelope drugs. Antimicrob Agents Chemother 2005, 49:3926-3929.
31. Weng J., Krementsov D.N., Khurana S., Roy N.H., Thali M. Formation of syncytia is repressed by tetraspanins in human immunodeficiency virus type 1-producing cells. J Virol 2009, 83:7467-7474.
32. Doria-Rose N.A., Klein R.M., Daniels M.G., O'Dell S., Nason M., Lapedes A., et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol 2010, 84:1631-1636.
33. Li Y., Migueles S.A., Welcher B., Svehla K., Phogat A., Louder M.K., et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007, 13:1032-1034.
34. Pietzsch J., Scheid J.F., Mouquet H., Klein F., Seaman M.S., Jankovic M., et al. Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. J Exp Med 2010, 207:1995.
35. Corti D., Langedijk J.P., Hinz A., Seaman M.S., Vanzetta F., Fernandez-Rodriguez B.M., et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010, 5:e8805.
36. Pancera M., McLellan J.S., Wu X., Zhu J., Changela A., Schmidt S.D., et al. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 2010, 84:8098-8110.
37. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000, 6:207-210.